EQUEST ORAL GEL, 18.92 MG/G, ORAL GEL FOR HORSES AND PONIES
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
04-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
MOXIDECTIN
Available from:
Pfizer Healthcare Ireland
ATC code:
QP54AB02
Dosage:
18.92 mg/g
Pharmaceutical form:
Oral Gel
Therapeutic group:
Endectoparasiticides
Therapeutic area:
Equine - Food
Authorization date:
2011-03-25
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
EQUEST ORAL GEL, 18.92 mg/g, oral gel for horses and ponies
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each g contains:
ACTIVE SUBSTANCES
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral Gel
Yellow gel.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses and ponies
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The veterinary medicinal product is indicated for treatment of infections caused by moxidectin sensitive strains of:
Large strongyles:
_Strongylus vulgaris _(adults and arterial stages)
_Strongylus edentatus _(adults and visceral stages)
_Triodontophorus brevicauda _(adults)
_Triodontophorus serratus _(adults)
_Triodontophorus tenuicollis _(adults)
Small strongyles (adults and intraluminal larval stages):
_Cyathostomum _spp.
_Cylicocyclus _spp_._
_Cylicostephanus _spp_._
_Cylicodontophorus _spp.
_Gyalocephalus _spp.
Ascarids:
_Parascaris equorum _(adult and larval stages)
Moxidectin
18.92 mg
Excipients qsp
Benzyl Alcohol
37.84 mg
Disodium Edetate
0.24 mg
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 01/12/2011_
_CRN 7011267_
_page number: 1_
Other species:
_Oxyuris equi _(adult and larval stages)
_Habronema muscae _(adults)
_Gasterophilus intestinalis _(L2, L3)
_Gasterophilus nasalis _(L2, L3)
_Strongyloides westeri _(adults)
_Trichostrongylus axei_
The veterinary medicinal product has a persistent efficacy of two weeks against small strongyles. The excretion of
small strongyles eggs is suppressed for 90 days.
The veterinary medicinal product is effective against (developing) intramucosal L4 stages of small strongyles. At 8
weeks after treatment, early (hypobiotic) EL3 stages of small strongyles are eliminated.
4.3 CONTRAI
Read the complete document
